Rationale, design, and methodology of a prospective cohort study for coping with Behavioral and Psychological Symptoms of Dementia: the RECage project

Manuscript Number: 

20-1215R2

Author(s): 
Sverre Bergh, Bruno Mario Cesana, Alfonso Ciccone, Carlo Alberto Defanti, Andrea Fabbo, Sara Fascendini, Giovanni B. Frisoni, Lutz Frölich, Anna Giulia Guazzarini, Jacques Hugon, Sara Lavolpe, Patrizia Mecocci, Oliver Peters, Eleni Poptsi, Magda Tsolaki

Disclosures

Sverre Bergh

  • Nothing to Disclose

Bruno Mario Cesana

  • Nothing to Disclose

Alfonso Ciccone

  • Nothing to Disclose

Carlo Alberto Defanti

  • Nothing to Disclose

Andrea Fabbo

  • Nothing to Disclose

Sara Fascendini

  • Nothing to Disclose

Giovanni B. Frisoni

  • Nothing to Disclose

Lutz Frölich

  • Consulting Fees:
    Consulting: Abbott, Allergan, Axon Neuroscience, Biogen, Eisai, InfectoPharm, MerckSharpe & Dohme, Novo Nordisk, Roche, Schwabe Pharma
    Lecture Fees:
    Eisai, Roche

Anna Giulia Guazzarini

  • Nothing to Disclose

Jacques Hugon

  • Consulting Fees:
    Paid advisory board: Protek Therapeutic
    Grants
    • Agency: 
      Center of Cognitive Neurology : Protekt Therapeutics

Sara Lavolpe

  • Nothing to Disclose

Patrizia Mecocci

  • Nothing to Disclose

Oliver Peters

  • Consulting Fees:
    Biogen, Roche, Griffols
    Lecture Fees:
    Roche, Biogen, Eisai, Schwabe
    Grants
    • Agency: 
      Biogen
      Dates: 
      2016-2021
    • Agency: 
      Roche
      Dates: 
      2017-2021
    • Agency: 
      Novartis
      Dates: 
      2018-2019
    • Agency: 
      Pharmatrophix
      Dates: 
      2017-2021
    • Agency: 
      Eisai
      Dates: 
      2020-2021

Eleni Poptsi

  • Nothing to Disclose

Magda Tsolaki

  • Nothing to Disclose